Optical Coherence Tomography Angiography for the Characterisation of Retinal Microvasculature Alterations in Pregnant Patients with Anaemia: a Nested Case‒control Study.
Yuxuan Wu,Dongyu Wang,Xiaohang Wu,Lixia Shen,Lanqin Zhao,Wei Wang,Hui Xiao,Xun Wang,Lixue Liu,Zhenzhe Lin,Jingyuan Yang,Xiaohong Lin,Dongyuan Yun,Wai Cheng Iao,Yi Wu,Miaohong Xu,Kexin Song,Zemeihong Xu,Yihong Huang,Shaole Shi,Mo Zhang,Junling Zhou,Zhuofan Yang,Zilian Wang,Haotian Lin
DOI: https://doi.org/10.1136/bjo-2022-321781
2024-01-01
British Journal of Ophthalmology
Abstract:AimsTo characterise retinal microvascular alterations in the eyes of pregnant patients with anaemia (PA) and to compare the alterations with those in healthy controls (HC) using optical coherence tomography angiography (OCTA).MethodsThis nested case‒control study included singleton PA and HC from the Eye Health in Pregnancy Study. Fovea avascular zone (FAZ) metrics, perfusion density (PD) in the superficial capillary plexus, deep capillary plexus and flow deficit (FD) density in the choriocapillaris (CC) were quantified using FIJI software. Linear regressions were conducted to evaluate the differences in OCTA metrics between PA and HC. Subgroup analyses were performed based on comparisons between PA diagnosed in the early or late trimester and HC.ResultsIn total, 99 eyes of 99 PA and 184 eyes of 184 HC were analysed. PA had a significantly reduced FAZ perimeter (βcoefficient=−0.310, p<0.001), area (βcoefficient=−0.121, p=0.001) and increased circularity (βcoefficient=0.037, p<0.001) compared with HC. Furthermore, higher PD in the central (βcoefficient=0.327, p=0.001) and outer (βcoefficient=0.349, p=0.007) regions were observed in PA. PA diagnosed in the first trimester had more extensive central FD (βcoefficient=4.199, p=0.003) in the CC, indicating impaired perfusion in the CC.ConclusionIt was found that anaemia during pregnancy was associated with macular microvascular abnormalities, which differed in PA as pregnancy progressed. The results suggest that quantitative OCTA metrics may be useful for risk evaluation before clinical diagnosis.Trial registration numbers2021KYPJ098 and ChiCTR2100049850.